Aetna International is set to take over Aviva UK’s IPMI division

By Catherine Sturman
Leading global health care benefits provider, Aetna International has entered an agreement to acquire Aviva UK’s International Private Medical Insuran...

Leading global health care benefits provider, Aetna International has entered an agreement to acquire Aviva UK’s International Private Medical Insurance (IPMI) operations. From May 2018, Aviva UK will no longer provide IPMI cover for new customers or for existing customers wishing to renew their policies. 

Serving over 700,000 million members worldwide, Aetna International offers a multitude of services, delivering comprehensive health care benefits, alongside customised technological and health management solutions, covering health care systems, government entities and large employers.

Under the agreement, existing Aviva IPMI customers will be offered continuation terms at policy renewal with Aetna International. Existing Aviva customers who renew their policy will then become Aetna customers and will no longer have a relationship with Aviva.

See also

David Healy, CEO EMEA at Aetna International said: “We are delighted to have reached this agreement with Aviva. 

We are committed to delivering Aviva’s IPMI customers continuation of cover with Aetna that provides comparable benefits and an excellent level of service. This is very much in line with our business strategy to deliver comprehensive health care benefits worldwide.

Our scale, expertise, customer service infrastructure and technological focus in IPMI allow us to make a significant contribution to improving people’s health and the quality of care they receive.”

Share

Featured Articles

UnitedHealth CEO Admits Hack hit Third of US Citizens' Data

UnitedHealth Group CEO Andrew Witty tells stunned US congressional hearing Change Healthcare cyberattack affects third of the US population

Why Sanofi Leads the way on Healthcare Sustainability

How French multinational Sanofi is ensuring delivery of essential medical supplies while being ESG-compliant

Philips Q1 Results hit by $1.1bn Respironics Settlement

As Royal Philips reports Q1 2024 results we profile the Netherlands-based healthcare technology company, who made the switch from consumer electronics

Vaccine Breakthrough on Antibiotics Resistant Diseases

Medical Devices & Pharma

Oracle Fusion Cloud Update Boost for Patients

Technology & AI

WHO Tightens air Quality Guidelines as Pollution Kills 7mn

Sustainability